{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:28:18Z","timestamp":1778693298281,"version":"3.51.4"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,20]]},"DOI":"10.7759\/cureus.17321","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T13:23:11Z","timestamp":1629465791000},"source":"Crossref","is-referenced-by-count":5,"title":["Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus"],"prefix":"10.7759","author":[{"given":"Jaskamal","family":"Padda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khizer","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anwar","family":"Khedr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahriba","family":"Tasnim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ola A","family":"Al-Ewaidat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayden Charlene","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gutteridge","family":"Jean-Charles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3109\/10408363.2011.596521","article-title":"Non-alcoholic fatty liver disease","volume":"48","author":"Smith BW","year":"2011","unstructured":"Smith BW, Adams LA. Non-alcoholic fatty liver disease. Crit Rev Clin Lab Sci. 2011, 48:97-113. 10.3109\/10408363.2011.596521","journal-title":"Crit Rev Clin Lab Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001235","article-title":"Nonalcoholic fatty liver disease: current concepts, epidemiology and management strategies","volume":"30","author":"Tomic D","year":"2018","unstructured":"Tomic D, Kemp WW, Roberts SK. Nonalcoholic fatty liver disease: current concepts, epidemiology and management strategies. Eur J Gastroenterol Hepatol. 2018, 30:1103-15. 10.1097\/MEG.0000000000001235","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention","volume":"18","author":"Huang DQ","year":"2021","unstructured":"Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021, 18:223-38. 10.1038\/s41575-020-00381-6","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.21037\/tgh.2019.09.08","article-title":"Epidemiology of non-alcoholic and alcoholic fatty liver diseases","volume":"5","author":"Mitra S","year":"2020","unstructured":"Mitra S, De A, Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases. Transl Gastroenterol Hepatol. 2020, 5:16. 10.21037\/tgh.2019.09.08","journal-title":"Transl Gastroenterol Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i47.8263","article-title":"Clinical epidemiology and disease burden of nonalcoholic fatty liver disease","volume":"23","author":"Perumpail BJ","year":"2017","unstructured":"Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol. 2017, 23:8263-76. 10.3748\/wjg.v23.i47.8263","journal-title":"World J Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2011.03.020","article-title":"Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008","volume":"9","author":"Younossi ZM","year":"2011","unstructured":"Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, Srishord M. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011, 9:524-30. 10.1016\/j.cgh.2011.03.020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X17725977","article-title":"Association between physical activity and risk of nonalcoholic fatty liver disease: a meta-analysis","volume":"10","author":"Qiu S","year":"2017","unstructured":"Qiu S, Cai X, Sun Z, Li L, Z\u00fcgel M, Steinacker JM, Schumann U. Association between physical activity and risk of nonalcoholic fatty liver disease: a meta-analysis. Therap Adv Gastroenterol. 2017, 10:701-13. 10.1177\/1756283X17725977","journal-title":"Therap Adv Gastroenterol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00448-y","article-title":"The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments (Epub ahead of print)","author":"Targher G","year":"2021","unstructured":"Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments (Epub ahead of print). Nat Rev Gastroenterol Hepatol. 2021, 10.1038\/s41575-021-00448-y","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v7.i11.1450","article-title":"Non-alcoholic fatty liver disease in 2015","volume":"7","author":"Ahmed M","year":"2015","unstructured":"Ahmed M. Non-alcoholic fatty liver disease in 2015. World J Hepatol. 2015, 7:1450-9. 10.4254\/wjh.v7.i11.1450","journal-title":"World J Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2174\/1381612825666190117102111","article-title":"Diagnosis of non-alcoholic fatty liver disease (NAFLD): current concepts","volume":"24","author":"Papatheodoridi M","year":"2018","unstructured":"Papatheodoridi M, Cholongitas E. Diagnosis of non-alcoholic fatty liver disease (NAFLD): current concepts. Curr Pharm Des. 2018, 24:4574-86. 10.2174\/1381612825666190117102111","journal-title":"Curr Pharm Des"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12271","article-title":"Characteristics and diagnosis of NAFLD\/NASH","volume":"28","author":"Hashimoto E","year":"2013","unstructured":"Hashimoto E, Taniai M, Tokushige K. Characteristics and diagnosis of NAFLD\/NASH. J Gastroenterol Hepatol. 2013, 28:64-70. 10.1111\/jgh.12271","journal-title":"J Gastroenterol Hepatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcp158","article-title":"Pathogenesis of non-alcoholic fatty liver disease","volume":"103","author":"Dowman JK","year":"2010","unstructured":"Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. QJM. 2010, 103:71-83. 10.1093\/qjmed\/hcp158","journal-title":"QJM"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2016.01.001","article-title":"Non-alcoholic fatty liver disease and diabetes","volume":"65","author":"Hazlehurst JM","year":"2016","unstructured":"Hazlehurst JM, Woods C, Marjot T, Cobbold JF, Tomlinson JW. Non-alcoholic fatty liver disease and diabetes. Metabolism. 2016, 65:1096-108. 10.1016\/j.metabol.2016.01.001","journal-title":"Metabolism"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20283","article-title":"Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway","volume":"40","author":"Feldstein AE","year":"2004","unstructured":"Feldstein AE, Werneburg NW, Canbay A, et al.. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology. 2004, 40:185-94. 10.1002\/hep.20283","journal-title":"Hepatology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1091981","article-title":"Mechanisms of disease progression in nonalcoholic fatty liver disease","volume":"28","author":"Jou J","year":"2008","unstructured":"Jou J, Choi SS, Diehl AM. Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis. 2008, 28:370-9. 10.1055\/s-0028-1091981","journal-title":"Semin Liver Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/3920196","article-title":"The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD)","volume":"2020","author":"Tanase DM","year":"2020","unstructured":"Tanase DM, Gosav EM, Costea CF, et al.. The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD). J Diabetes Res. 2020, 2020:3920196. 10.1155\/2020\/3920196","journal-title":"J Diabetes Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1210\/er.2019-00034","article-title":"The liver as an endocrine organ-linking NAFLD and insulin resistance","volume":"40","author":"Watt MJ","year":"2019","unstructured":"Watt MJ, Miotto PM, De Nardo W, Montgomery MK. The liver as an endocrine organ-linking NAFLD and insulin resistance. Endocr Rev. 2019, 40:1367-93. 10.1210\/er.2019-00034","journal-title":"Endocr Rev"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21113863","article-title":"The role of insulin resistance and diabetes in nonalcoholic fatty liver disease","volume":"21","author":"Fujii H","year":"2020","unstructured":"Fujii H, Kawada N, Japan Study Group Of Nafld Jsg-Nafld. The role of insulin resistance and diabetes in nonalcoholic fatty liver disease. Int J Mol Sci. 2020, 21:3863. 10.3390\/ijms21113863","journal-title":"Int J Mol Sci"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2337\/db09-0279","article-title":"Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene","volume":"58","author":"Kantartzis K","year":"2009","unstructured":"Kantartzis K, Peter A, Machicao F, et al.. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes. 2009, 58:2616-23. 10.2337\/db09-0279","journal-title":"Diabetes"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2016.147","article-title":"NAFLD and diabetes mellitus","volume":"14","author":"Tilg H","year":"2017","unstructured":"Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017, 14:32-42. 10.1038\/nrgastro.2016.147","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2019.34.3.226","article-title":"Nonalcoholic fatty liver disease and diabetes: an epidemiological perspective","volume":"34","author":"Rhee EJ","year":"2019","unstructured":"Rhee EJ. Nonalcoholic fatty liver disease and diabetes: an epidemiological perspective. Endocrinol Metab (Seoul). 2019, 34:226-33. 10.3803\/EnM.2019.34.3.226","journal-title":"Endocrinol Metab (Seoul)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-1519","article-title":"Resolution of fatty liver and risk of incident diabetes","volume":"98","author":"Sung KC","year":"2013","unstructured":"Sung KC, Wild SH, Byrne CD. Resolution of fatty liver and risk of incident diabetes. J Clin Endocrinol Metab. 2013, 98:3637-43. 10.1210\/jc.2013-1519","journal-title":"J Clin Endocrinol Metab"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2017.10.019","article-title":"The persistence of fatty liver has a differential impact on the development of diabetes: The Kangbuk Samsung Health Study","volume":"135","author":"Bae JC","year":"2018","unstructured":"Bae JC, Han JM, Cho JH, et al.. The persistence of fatty liver has a differential impact on the development of diabetes: The Kangbuk Samsung Health Study. Diabetes Res Clin Pract. 2018, 135:1-6. 10.1016\/j.diabres.2017.10.019","journal-title":"Diabetes Res Clin Pract"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2010.518623","article-title":"Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity","volume":"43","author":"Musso G","year":"2011","unstructured":"Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011, 43:617-49. 10.3109\/07853890.2010.518623","journal-title":"Ann Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13264","article-title":"Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis","volume":"31","author":"Ballestri S","year":"2016","unstructured":"Ballestri S, Zona S, Targher G, et al.. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016, 31:936-44. 10.1111\/jgh.13264","journal-title":"J Gastroenterol Hepatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1902","article-title":"Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis","volume":"41","author":"Mantovani A","year":"2018","unstructured":"Mantovani A, Byrne CD, Bonora E, Targher G. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis. Diabetes Care. 2018, 41:372-82. 10.2337\/dc17-1902","journal-title":"Diabetes Care"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v7.i4.638","article-title":"Non-invasive methods for the diagnosis of nonalcoholic fatty liver disease","volume":"7","author":"Papagianni M","year":"2015","unstructured":"Papagianni M, Sofogianni A, Tziomalos K. Non-invasive methods for the diagnosis of nonalcoholic fatty liver disease. World J Hepatol. 2015, 7:638-48. 10.4254\/wjh.v7.i4.638","journal-title":"World J Hepatol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13174","article-title":"Increased prevalence and risk of non-alcoholic fatty liver disease in overweight and obese patients with type 2 diabetes in South China","volume":"34","author":"Yi M","year":"2017","unstructured":"Yi M, Chen RP, Yang R, Chen H. Increased prevalence and risk of non-alcoholic fatty liver disease in overweight and obese patients with type 2 diabetes in South China. Diabet Med. 2017, 34:505-13. 10.1111\/dme.13174","journal-title":"Diabet Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008179","article-title":"Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a meta-analysis","volume":"96","author":"Dai W","year":"2017","unstructured":"Dai W, Ye L, Liu A, Wen SW, Deng J, Wu X, Lai Z. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a meta-analysis. Medicine (Baltimore). 2017, 96:e8179. 10.1097\/MD.0000000000008179","journal-title":"Medicine (Baltimore)"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1966","article-title":"High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels","volume":"100","author":"Portillo-Sanchez P","year":"2015","unstructured":"Portillo-Sanchez P, Bril F, Maximos M, et al.. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J Clin Endocrinol Metab. 2015, 100:2231-8. 10.1210\/jc.2015-1966","journal-title":"J Clin Endocrinol Metab"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.2337\/dc07-0349","article-title":"Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients","volume":"30","author":"Targher G","year":"2007","unstructured":"Targher G, Bertolini L, Rodella S, Tessari R, Zenari L, Lippi G, Arcaro G. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care. 2007, 30:2119-21. 10.2337\/dc07-0349","journal-title":"Diabetes Care"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.10001","article-title":"Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention","volume":"11","author":"Wu Y","year":"2014","unstructured":"Wu Y, Ding Y, Tanaka Y, Zhang W. Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention. Int J Med Sci. 2014, 11:1185-200. 10.7150\/ijms.10001","journal-title":"Int J Med Sci"},{"key":"ref33","article-title":"Screening for nonalcoholic fatty liver disease in the primary care clinic","volume":"15","author":"Pandyarajan V","year":"2019","unstructured":"Pandyarajan V, Gish RG, Alkhouri N, Noureddin M. Screening for nonalcoholic fatty liver disease in the primary care clinic. Gastroenterol Hepatol (N Y). 2019, 15:357-65.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13405","article-title":"Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE","volume":"43","author":"Doycheva I","year":"2016","unstructured":"Doycheva I, Cui J, Nguyen P, et al.. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharmacol Ther. 2016, 43:83-95. 10.1111\/apt.13405","journal-title":"Aliment Pharmacol Ther"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.02.032","article-title":"Not routine screening, but vigilance for chronic liver disease in patients with type 2 diabetes","volume":"64","author":"Wong VW","year":"2016","unstructured":"Wong VW, Chalasani N. Not routine screening, but vigilance for chronic liver disease in patients with type 2 diabetes. J Hepatol. 2016, 64:1211-3. 10.1016\/j.jhep.2016.02.032","journal-title":"J Hepatol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1080\/00365520410006431","article-title":"High prevalence of metabolic complications in patients with non-alcoholic fatty liver disease","volume":"39","author":"Friis-Liby I","year":"2004","unstructured":"Friis-Liby I, Aldenborg F, Jerlstad P, Rundstr\u00f6m K, Bj\u00f6rnsson E. High prevalence of metabolic complications in patients with non-alcoholic fatty liver disease. Scand J Gastroenterol. 2004, 39:864-9. 10.1080\/00365520410006431","journal-title":"Scand J Gastroenterol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2006.04781.x","article-title":"Effects of nonalcoholic fatty liver disease on the development of metabolic disorders","volume":"22","author":"Fan JG","year":"2007","unstructured":"Fan JG, Li F, Cai XB, Peng YD, Ao QH, Gao Y. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J Gastroenterol Hepatol. 2007, 22:1086-91. 10.1111\/j.1440-1746.2006.04781.x","journal-title":"J Gastroenterol Hepatol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-3093","article-title":"Clinical Review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications","volume":"98","author":"Targher G","year":"2013","unstructured":"Targher G, Byrne CD. Clinical Review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab. 2013, 98:483-95. 10.1210\/jc.2012-3093","journal-title":"J Clin Endocrinol Metab"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2016.09.008","article-title":"Non-alcoholic fatty liver disease is associated with late but not early atherosclerotic lesions in Chinese inpatients with type 2 diabetes","volume":"31","author":"Guo K","year":"2017","unstructured":"Guo K, Zhang L, Lu J, et al.. Non-alcoholic fatty liver disease is associated with late but not early atherosclerotic lesions in Chinese inpatients with type 2 diabetes. J Diabetes Complications. 2017, 31:80-5. 10.1016\/j.jdiacomp.2016.09.008","journal-title":"J Diabetes Complications"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-2247","article-title":"Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients","volume":"30","author":"Targher G","year":"2007","unstructured":"Targher G, Bertolini L, Padovani R, et al.. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007, 30:1212-8. 10.2337\/dc06-2247","journal-title":"Diabetes Care"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis","volume":"65","author":"Targher G","year":"2016","unstructured":"Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016, 65:589-600. 10.1016\/j.jhep.2016.05.013","journal-title":"J Hepatol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.05.019","article-title":"CKD and nonalcoholic fatty liver disease","volume":"64","author":"Targher G","year":"2014","unstructured":"Targher G, Chonchol MB, Byrne CD. CKD and nonalcoholic fatty liver disease. Am J Kidney Dis. 2014, 64:638-52. 10.1053\/j.ajkd.2014.05.019","journal-title":"Am J Kidney Dis"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-007-0897-4","article-title":"Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative\/laser-treated retinopathy in type 2 diabetic patients","volume":"51","author":"Targher G","year":"2008","unstructured":"Targher G, Bertolini L, Rodella S, Zoppini G, Lippi G, Day C, Muggeo M. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative\/laser-treated retinopathy in type 2 diabetic patients. Diabetologia. 2008, 51:444-50. 10.1007\/s00125-007-0897-4","journal-title":"Diabetologia"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2007101155","article-title":"Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease","volume":"19","author":"Targher G","year":"2008","unstructured":"Targher G, Chonchol M, Bertolini L, et al.. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol. 2008, 19:1564-70. 10.1681\/ASN.2007101155","journal-title":"J Am Soc Nephrol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2704","article-title":"Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes","volume":"37","author":"Targher G","year":"2014","unstructured":"Targher G, Mantovani A, Pichiri I, et al.. Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes. Diabetes Care. 2014, 37:1729-36. 10.2337\/dc13-2704","journal-title":"Diabetes Care"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2017.01.024","article-title":"Nonalcoholic fatty liver disease is associated with an increased prevalence of distal symmetric polyneuropathy in adult patients with type 1 diabetes","volume":"31","author":"Mantovani A","year":"2017","unstructured":"Mantovani A, Rigolon R, Mingolla L, et al.. Nonalcoholic fatty liver disease is associated with an increased prevalence of distal symmetric polyneuropathy in adult patients with type 1 diabetes. J Diabetes Complications. 2017, 31:1021-6. 10.1016\/j.jdiacomp.2017.01.024","journal-title":"J Diabetes Complications"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2015.06.015","article-title":"An association of large-fibre peripheral nerve dysfunction with non-invasive measures of liver fibrosis secondary to non-alcoholic fatty liver disease in diabetes","volume":"29","author":"Williams KH","year":"2015","unstructured":"Williams KH, Burns K, Constantino M, et al.. An association of large-fibre peripheral nerve dysfunction with non-invasive measures of liver fibrosis secondary to non-alcoholic fatty liver disease in diabetes. J Diabetes Complications. 2015, 29:1240-7. 10.1016\/j.jdiacomp.2015.06.015","journal-title":"J Diabetes Complications"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1239","article-title":"Clinical model for NASH and advanced fibrosis in adult patients with diabetes and NAFLD: guidelines for referral in NAFLD","volume":"38","author":"Bazick J","year":"2015","unstructured":"Bazick J, Donithan M, Neuschwander-Tetri BA, et al.. Clinical model for NASH and advanced fibrosis in adult patients with diabetes and NAFLD: guidelines for referral in NAFLD. Diabetes Care. 2015, 38:1347-55. 10.2337\/dc14-1239","journal-title":"Diabetes Care"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2010.506375","article-title":"Population-based risk factors and resource utilization for HCC: US perspective","volume":"26","author":"Sanyal A","year":"2010","unstructured":"Sanyal A, Poklepovic A, Moyneur E, Barghout V. Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin. 2010, 26:2183-91. 10.1185\/03007995.2010.506375","journal-title":"Curr Med Res Opin"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.10.065","article-title":"Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma","volume":"126","author":"El-Serag HB","year":"2004","unstructured":"El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004, 126:460-8. 10.1053\/j.gastro.2003.10.065","journal-title":"Gastroenterology"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2011.01.023","article-title":"Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma","volume":"9","author":"Yasui K","year":"2011","unstructured":"Yasui K, Hashimoto E, Komorizono Y, et al.. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011, 9:428-33. 10.1016\/j.cgh.2011.01.023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27016","article-title":"Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer","volume":"60","author":"Aleksandrova K","year":"2014","unstructured":"Aleksandrova K, Boeing H, N\u00f6thlings U, et al.. Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer. Hepatology. 2014, 60:858-71. 10.1002\/hep.27016","journal-title":"Hepatology"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2010.173","article-title":"Nonalcoholic fatty liver disease: liver disease: an overlooked complication of diabetes mellitus","volume":"6","author":"Arrese M","year":"2010","unstructured":"Arrese M. Nonalcoholic fatty liver disease: liver disease: an overlooked complication of diabetes mellitus. Nat Rev Endocrinol. 2010, 6:660-1. 10.1038\/nrendo.2010.173","journal-title":"Nat Rev Endocrinol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.P076034","article-title":"Novel association of TM6SF2 rs58542926 genotype with increased serum tyrosine levels and decreased apoB-100 particles in Finns","volume":"58","author":"Kim DS","year":"2017","unstructured":"Kim DS, Jackson AU, Li YK, et al.. Novel association of TM6SF2 rs58542926 genotype with increased serum tyrosine levels and decreased apoB-100 particles in Finns. J Lipid Res. 2017, 58:1471-81. 10.1194\/jlr.P076034","journal-title":"J Lipid Res"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.222844","article-title":"Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C","volume":"60","author":"Miquilena-Colina ME","year":"2011","unstructured":"Miquilena-Colina ME, Lima-Cabello E, S\u00e1nchez-Campos S, et al.. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C. Gut. 2011, 60:1394-402. 10.1136\/gut.2010.222844","journal-title":"Gut"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26604","article-title":"Free cholesterol accumulation in hepatic stellate cells: mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice","volume":"59","author":"Tomita K","year":"2014","unstructured":"Tomita K, Teratani T, Suzuki T, et al.. Free cholesterol accumulation in hepatic stellate cells: mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice. Hepatology. 2014, 59:154-69. 10.1002\/hep.26604","journal-title":"Hepatology"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.11.014","article-title":"Lipotoxicity and the gut-liver axis in NASH pathogenesis","volume":"68","author":"Marra F","year":"2018","unstructured":"Marra F, Svegliati-Baroni G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol. 2018, 68:280-95. 10.1016\/j.jhep.2017.11.014","journal-title":"J Hepatol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i39.14205","article-title":"Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease","volume":"20","author":"Paradies G","year":"2014","unstructured":"Paradies G, Paradies V, Ruggiero FM, Petrosillo G. Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease. World J Gastroenterol. 2014, 20:14205-18. 10.3748\/wjg.v20.i39.14205","journal-title":"World J Gastroenterol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.07.018","article-title":"Cell death and cell death responses in liver disease: mechanisms and clinical relevance","volume":"147","author":"Luedde T","year":"2014","unstructured":"Luedde T, Kaplowitz N, Schwabe RF. Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology. 2014, 147:765-83. 10.1053\/j.gastro.2014.07.018","journal-title":"Gastroenterology"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26592","article-title":"NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice","volume":"59","author":"Wree A","year":"2014","unstructured":"Wree A, Eguchi A, McGeough MD, et al.. NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. Hepatology. 2014, 59:898-910. 10.1002\/hep.26592","journal-title":"Hepatology"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1042\/CS20170175","article-title":"Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease","volume":"131","author":"Dongiovanni P","year":"2017","unstructured":"Dongiovanni P, Meroni M, Baselli GA, et al.. Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease. Clin Sci (Lond). 2017, 131:1301-15. 10.1042\/CS20170175","journal-title":"Clin Sci (Lond)"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.04.001","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology","volume":"142","author":"Chalasani N","year":"2012","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al.. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012, 142:1592-609. 10.1053\/j.gastro.2012.04.001","journal-title":"Gastroenterology"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease: a systematic review","volume":"313","author":"Rinella ME","year":"2015","unstructured":"Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015, 313:2263-73. 10.1001\/jama.2015.5370","journal-title":"JAMA"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","author":"European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO)","year":"2016","unstructured":"European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016, 64:1388-402. 10.1016\/j.jhep.2015.11.004","journal-title":"J Hepatol"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.3390\/cells9041005","article-title":"Noninvasive diagnosis of NAFLD and NASH","volume":"9","author":"Piazzolla VA","year":"2020","unstructured":"Piazzolla VA, Mangia A. Noninvasive diagnosis of NAFLD and NASH. Cells. 2020, 9:1005. 10.3390\/cells9041005","journal-title":"Cells"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22429","article-title":"Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes","volume":"48","author":"Fracanzani AL","year":"2008","unstructured":"Fracanzani AL, Valenti L, Bugianesi E, et al.. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology. 2008, 48:792-8. 10.1002\/hep.22429","journal-title":"Hepatology"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/2096161","article-title":"Circulating miRNAs as novel diagnostic biomarkers in nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"2019","author":"Cai C","year":"2019","unstructured":"Cai C, Lin Y, Yu C. Circulating miRNAs as novel diagnostic biomarkers in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Can J Gastroenterol Hepatol. 2019, 2019:2096161. 10.1155\/2019\/2096161","journal-title":"Can J Gastroenterol Hepatol"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.01.010","article-title":"Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease","volume":"60","author":"McPherson S","year":"2014","unstructured":"McPherson S, Henderson E, Burt AD, Day CP, Anstee QM. Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol. 2014, 60:1055-62. 10.1016\/j.jhep.2014.01.010","journal-title":"J Hepatol"},{"key":"ref69","article-title":"Nonalcoholic Fatty Liver Disease: Identifying Patients at Risk of Inflammation or Fibrosis","volume":"95","author":"Osayande AS","year":"2017","unstructured":"Osayande AS, Kale N. Nonalcoholic Fatty Liver Disease: Identifying Patients at Risk of Inflammation or Fibrosis. Am Fam Physician. 2017, 95:796-7.","journal-title":"Am Fam Physician"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.12384","article-title":"Advances in noninvasive methods for diagnosing nonalcoholic fatty liver disease","volume":"17","author":"Shen FF","year":"2016","unstructured":"Shen FF, Lu LG. Advances in noninvasive methods for diagnosing nonalcoholic fatty liver disease. J Dig Dis. 2016, 17:565-71. 10.1111\/1751-2980.12384","journal-title":"J Dig Dis"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i40.6053","article-title":"Ultrasound-based techniques for the diagnosis of liver steatosis","volume":"25","author":"Ferraioli G","year":"2019","unstructured":"Ferraioli G, Soares Monteiro LB. Ultrasound-based techniques for the diagnosis of liver steatosis. World J Gastroenterol. 2019, 25:6053-62. 10.3748\/wjg.v25.i40.6053","journal-title":"World J Gastroenterol"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24452","article-title":"Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis","volume":"54","author":"Hernaez R","year":"2011","unstructured":"Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, Clark JM. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011, 54:1082-90. 10.1002\/hep.24452","journal-title":"Hepatology"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz099","article-title":"Steatosis rates by liver biopsy and transient elastography with controlled attenuation parameter in clinical experience of hepatitis C virus (HCV) and human immunodeficiency virus\/HCV coinfection in a large US hepatitis clinic","volume":"6","author":"Sansom SE","year":"2019","unstructured":"Sansom SE, Martin J, Adeyemi O, et al.. Steatosis rates by liver biopsy and transient elastography with controlled attenuation parameter in clinical experience of hepatitis C virus (HCV) and human immunodeficiency virus\/HCV coinfection in a large US hepatitis clinic. Open Forum Infect Dis. 2019, 6:ofz099. 10.1093\/ofid\/ofz099","journal-title":"Open Forum Infect Dis"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12519","article-title":"Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: a meta-analysis of diagnostic accuracy","volume":"29","author":"Shi KQ","year":"2014","unstructured":"Shi KQ, Tang JZ, Zhu XL, et al.. Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: a meta-analysis of diagnostic accuracy. J Gastroenterol Hepatol. 2014, 29:1149-58. 10.1111\/jgh.12519","journal-title":"J Gastroenterol Hepatol"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.07.018","article-title":"Association between magnetic resonance imaging-proton density fat fraction and liver histology features in patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis","volume":"155","author":"Wildman-Tobriner B","year":"2018","unstructured":"Wildman-Tobriner B, Middleton MM, Moylan CA, et al.. Association between magnetic resonance imaging-proton density fat fraction and liver histology features in patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis. Gastroenterology. 2018, 155:1428-35. 10.1053\/j.gastro.2018.07.018","journal-title":"Gastroenterology"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12569","article-title":"Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments","volume":"39","author":"Kwok R","year":"2014","unstructured":"Kwok R, Tse YK, Wong GL, et al.. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther. 2014, 39:254-69. 10.1111\/apt.12569","journal-title":"Aliment Pharmacol Ther"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani N","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al.. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018, 67:328-57. 10.1002\/hep.29367","journal-title":"Hepatology"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2020.08.005","article-title":"Screening for nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography - a prospective, cross sectional study","volume":"82","author":"Mikolasevic I","year":"2020","unstructured":"Mikolasevic I, Domislovic V, Turk Wensveen T, et al.. Screening for nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography - a prospective, cross sectional study. Eur J Intern Med. 2020, 82:68-75. 10.1016\/j.ejim.2020.08.005","journal-title":"Eur J Intern Med"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1159\/000447276","article-title":"Extrahepatic diseases and NAFLD: the triangular relationship between NAFLD, type 2-diabetes and dysbiosis","volume":"34","author":"Scorletti E","year":"2016","unstructured":"Scorletti E, Byrne CD. Extrahepatic diseases and NAFLD: the triangular relationship between NAFLD, type 2-diabetes and dysbiosis. Dig Dis. 2016, 34:11-8. 10.1159\/000447276","journal-title":"Dig Dis"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01281-6","article-title":"Managing NAFLD in type 2 diabetes: the effect of lifestyle interventions, a narrative review","volume":"37","author":"Parry SA","year":"2020","unstructured":"Parry SA, Hodson L. Managing NAFLD in type 2 diabetes: the effect of lifestyle interventions, a narrative review. Adv Ther. 2020, 37:1381-406. 10.1007\/s12325-020-01281-6","journal-title":"Adv Ther"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X16638830","article-title":"Lifestyle changes for the treatment of nonalcoholic fatty liver disease: a review of observational studies and intervention trials","volume":"9","author":"Zelber-Sagi S","year":"2016","unstructured":"Zelber-Sagi S, Godos J, Salomone F. Lifestyle changes for the treatment of nonalcoholic fatty liver disease: a review of observational studies and intervention trials. Therap Adv Gastroenterol. 2016, 9:392-407. 10.1177\/1756283X16638830","journal-title":"Therap Adv Gastroenterol"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.110.007674","article-title":"Short-term weight loss and hepatic triglyceride reduction: evidence of a metabolic advantage with dietary carbohydrate restriction","volume":"93","author":"Browning JD","year":"2011","unstructured":"Browning JD, Baker JA, Rogers T, Davis J, Satapati S, Burgess SC. Short-term weight loss and hepatic triglyceride reduction: evidence of a metabolic advantage with dietary carbohydrate restriction. Am J Clin Nutr. 2011, 93:1048-52. 10.3945\/ajcn.110.007674","journal-title":"Am J Clin Nutr"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i28.9338","article-title":"Role of diet and lifestyle changes in nonalcoholic fatty liver disease","volume":"20","author":"Nseir W","year":"2014","unstructured":"Nseir W, Hellou E, Assy N. Role of diet and lifestyle changes in nonalcoholic fatty liver disease. World J Gastroenterol. 2014, 20:9338-44. 10.3748\/wjg.v20.i28.9338","journal-title":"World J Gastroenterol"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.06.020","article-title":"Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study","volume":"47","author":"Zelber-Sagi S","year":"2007","unstructured":"Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, Webb M, Blendis L, Halpern Z, Oren R. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol. 2007, 47:711-7. 10.1016\/j.jhep.2007.06.020","journal-title":"J Hepatol"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1002\/cld.1007","article-title":"The role of life style modifications in comprehensive non-alcoholic fatty liver disease treatment","volume":"17","author":"Viveiros K","year":"2021","unstructured":"Viveiros K. The role of life style modifications in comprehensive non-alcoholic fatty liver disease treatment. Clin Liver Dis (Hoboken). 2021, 17:11-4. 10.1002\/cld.1007","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-9-70","article-title":"The role of lifestyle changes in the management of chronic liver disease","volume":"9","author":"Nobili V","year":"2011","unstructured":"Nobili V, Carter-Kent C, Feldstein AE. The role of lifestyle changes in the management of chronic liver disease. BMC Med. 2011, 9:70. 10.1186\/1741-7015-9-70","journal-title":"BMC Med"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.3390\/ph11040121","article-title":"Antidiabetic drugs in NAFLD: the accomplishment of two goals at once?","volume":"11","author":"Tacelli M","year":"2018","unstructured":"Tacelli M, Celsa C, Magro B, Giannetti A, Pennisi G, Spatola F, Petta S. Antidiabetic drugs in NAFLD: the accomplishment of two goals at once?. Pharmaceuticals (Basel). 2018, 11:121. 10.3390\/ph11040121","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-011-2446-4","article-title":"Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials","volume":"55","author":"Musso G","year":"2012","unstructured":"Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia. 2012, 55:885-904. 10.1007\/s00125-011-2446-4","journal-title":"Diabetologia"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23623","article-title":"A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease","volume":"52","author":"Musso G","year":"2010","unstructured":"Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology. 2010, 52:79-104. 10.1002\/hep.23623","journal-title":"Hepatology"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.3892\/br.2012.18","article-title":"Metformin in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"1","author":"Li Y","year":"2013","unstructured":"Li Y, Liu L, Wang B, Wang J, Chen D. Metformin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Biomed Rep. 2013, 1:57-64. 10.3892\/br.2012.18","journal-title":"Biomed Rep"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04467.x","article-title":"Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis","volume":"32","author":"Rakoski MO","year":"2010","unstructured":"Rakoski MO, Singal AG, Rogers MA, Conjeevaram H. Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2010, 32:1211-21. 10.1111\/j.1365-2036.2010.04467.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2415","article-title":"Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients","volume":"96","author":"Nkontchou G","year":"2011","unstructured":"Nkontchou G, Cosson E, Aout M, et al.. Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J Clin Endocrinol Metab. 2011, 96:2601-8. 10.1210\/jc.2010-2415","journal-title":"J Clin Endocrinol Metab"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2010.02223.x","article-title":"Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease","volume":"30","author":"Donadon V","year":"2010","unstructured":"Donadon V, Balbi M, Mas MD, Casarin P, Zanette G. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int. 2010, 30:750-8. 10.1111\/j.1478-3231.2010.02223.x","journal-title":"Liver Int"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.2174\/1389200219666180416161846","article-title":"Anti-cancer effects of metformin: recent evidences for its role in prevention and treatment of cancer","volume":"19","author":"Kheirandish M","year":"2018","unstructured":"Kheirandish M, Mahboobi H, Yazdanparast M, Kamal W, Kamal MA. Anti-cancer effects of metformin: recent evidences for its role in prevention and treatment of cancer. Curr Drug Metab. 2018, 19:793-7. 10.2174\/1389200219666180416161846","journal-title":"Curr Drug Metab"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004529","article-title":"Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): a PRISMA-compliant systematic review and network meta-analysis","volume":"95","author":"Sawangjit R","year":"2016","unstructured":"Sawangjit R, Chongmelaxme B, Phisalprapa P, Saokaew S, Thakkinstian A, Kowdley KV, Chaiyakunapruk N. Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): a PRISMA-compliant systematic review and network meta-analysis. Medicine (Baltimore). 2016, 95:e4529. 10.1097\/MD.0000000000004529","journal-title":"Medicine (Baltimore)"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004947","article-title":"Thiazolidinediones for nonalcoholic steatohepatitis: a meta-analysis of randomized clinical trials","volume":"95","author":"He L","year":"2016","unstructured":"He L, Liu X, Wang L, Yang Z. Thiazolidinediones for nonalcoholic steatohepatitis: a meta-analysis of randomized clinical trials. Medicine (Baltimore). 2016, 95:e4947. 10.1097\/MD.0000000000004947","journal-title":"Medicine (Baltimore)"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.5604\/01.3001.0010.0284","article-title":"Meta-analysis of randomized controlled trials of pharmacologic agents in non-alcoholic steatohepatitis","volume":"16","author":"Said A","year":"2017","unstructured":"Said A, Akhter A. Meta-analysis of randomized controlled trials of pharmacologic agents in non-alcoholic steatohepatitis. Ann Hepatol. 2017, 16:538-47. 10.5604\/01.3001.0010.0284","journal-title":"Ann Hepatol"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27999","article-title":"Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: a systematic review and network meta-analysis","volume":"62","author":"Singh S","year":"2015","unstructured":"Singh S, Khera R, Allen AM, Murad MH, Loomba R. Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: a systematic review and network meta-analysis. Hepatology. 2015, 62:1417-32. 10.1002\/hep.27999","journal-title":"Hepatology"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02462.x","article-title":"Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis","volume":"31","author":"Svegliati-Baroni G","year":"2011","unstructured":"Svegliati-Baroni G, Saccomanno S, Rychlicki C, et al.. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int. 2011, 31:1285-97. 10.1111\/j.1478-3231.2011.02462.x","journal-title":"Liver Int"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.09.032","article-title":"Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase","volume":"54","author":"Ben-Shlomo S","year":"2011","unstructured":"Ben-Shlomo S, Zvibel I, Shnell M, et al.. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J Hepatol. 2011, 54:1214-23. 10.1016\/j.jhep.2010.09.032","journal-title":"J Hepatol"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1210\/en.2012-1937","article-title":"GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-\/-) mice","volume":"154","author":"Panjwani N","year":"2013","unstructured":"Panjwani N, Mulvihill EE, Longuet C, et al.. GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-\/-) mice. Endocrinology. 2013, 154:127-39. 10.1210\/en.2012-1937","journal-title":"Endocrinology"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23569","article-title":"Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway","volume":"51","author":"Gupta NA","year":"2010","unstructured":"Gupta NA, Mells J, Dunham RM, Grakoui A, Handy J, Saxena NK, Anania FA. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology. 2010, 51:1584-92. 10.1002\/hep.23569","journal-title":"Hepatology"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong MJ","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, et al.. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016, 387:679-90. 10.1016\/S0140-6736(15)00803-X","journal-title":"Lancet"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0146337","article-title":"The selective SGLT2 inhibitor ipragliflozin has a therapeutic effect on nonalcoholic steatohepatitis in mice","volume":"11","author":"Honda Y","year":"2016","unstructured":"Honda Y, Imajo K, Kato T, et al.. The selective SGLT2 inhibitor ipragliflozin has a therapeutic effect on nonalcoholic steatohepatitis in mice. PLoS One. 2016, 11:e0146337. 10.1371\/journal.pone.0146337","journal-title":"PLoS One"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151511","article-title":"Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction","volume":"11","author":"Komiya C","year":"2016","unstructured":"Komiya C, Tsuchiya K, Shiba K, et al.. Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction. PLoS One. 2016, 11:e0151511. 10.1371\/journal.pone.0151511","journal-title":"PLoS One"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2015.02.005","article-title":"Remogliflozin etabonate improves fatty liver disease in diet-induced obese male mice","volume":"5","author":"Nakano S","year":"2015","unstructured":"Nakano S, Katsuno K, Isaji M, et al.. Remogliflozin etabonate improves fatty liver disease in diet-induced obese male mice. J Clin Exp Hepatol. 2015, 5:190-8. 10.1016\/j.jceh.2015.02.005","journal-title":"J Clin Exp Hepatol"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2013.05.014","article-title":"Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice","volume":"715","author":"Tahara A","year":"2013","unstructured":"Tahara A, Kurosaki E, Yokono M, et al.. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol. 2013, 715:246-55. 10.1016\/j.ejphar.2013.05.014","journal-title":"Eur J Pharmacol"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2015.02.009","article-title":"Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats","volume":"754","author":"Hayashizaki-Someya Y","year":"2015","unstructured":"Hayashizaki-Someya Y, Kurosaki E, Takasu T, Mitori H, Yamazaki S, Koide K, Takakura S. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats. Eur J Pharmacol. 2015, 754:19-24. 10.1016\/j.ejphar.2015.02.009","journal-title":"Eur J Pharmacol"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-015-0102-8","article-title":"Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus","volume":"7","author":"Qiang S","year":"2015","unstructured":"Qiang S, Nakatsu Y, Seno Y, et al.. Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus. Diabetol Metab Syndr. 2015, 7:104. 10.1186\/s13098-015-0102-8","journal-title":"Diabetol Metab Syndr"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179960","article-title":"Effects of canagliflozin on weight loss in high-fat diet-induced obese mice","volume":"12","author":"Ji W","year":"2017","unstructured":"Ji W, Zhao M, Wang M, et al.. Effects of canagliflozin on weight loss in high-fat diet-induced obese mice. PLoS One. 2017, 12:e0179960. 10.1371\/journal.pone.0179960","journal-title":"PLoS One"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-016-0169-x","article-title":"Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes","volume":"8","author":"Jojima T","year":"2016","unstructured":"Jojima T, Tomotsune T, Iijima T, Akimoto K, Suzuki K, Aso Y. Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes. Diabetol Metab Syndr. 2016, 8:45. 10.1186\/s13098-016-0169-x","journal-title":"Diabetol Metab Syndr"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16874","article-title":"Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice","volume":"8","author":"Obara K","year":"2017","unstructured":"Obara K, Shirakami Y, Maruta A, et al.. Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice. Oncotarget. 2017, 8:58353-63. 10.18632\/oncotarget.16874","journal-title":"Oncotarget"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i15.2298","article-title":"Dipeptidyl peptidase-4: a key player in chronic liver disease","volume":"19","author":"Itou M","year":"2013","unstructured":"Itou M, Kawaguchi T, Taniguchi E, Sata M. Dipeptidyl peptidase-4: a key player in chronic liver disease. World J Gastroenterol. 2013, 19:2298-306. 10.3748\/wjg.v19.i15.2298","journal-title":"World J Gastroenterol"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.12669\/pjms.326.11133","article-title":"Vildagliptin ameliorates biochemical, metabolic and fatty changes associated with non alcoholic fatty liver disease","volume":"32","author":"Hussain M","year":"2016","unstructured":"Hussain M, Majeed Babar MZ, Hussain MS, Akhtar L. Vildagliptin ameliorates biochemical, metabolic and fatty changes associated with non alcoholic fatty liver disease. Pak J Med Sci. 2016, 32:1396-401. 10.12669\/pjms.326.11133","journal-title":"Pak J Med Sci"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198106030-00003","article-title":"Clinical pharmacokinetics of sulphonylurea hypoglycaemic drugs","volume":"6","author":"Balant L","year":"1981","unstructured":"Balant L. Clinical pharmacokinetics of sulphonylurea hypoglycaemic drugs. Clin Pharmacokinet. 1981, 6:215-41. 10.2165\/00003088-198106030-00003","journal-title":"Clin Pharmacokinet"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.2165\/11207600-000000000-00000","article-title":"Repaglinide: a review of its use in type 2 diabetes mellitus","volume":"72","author":"Scott LJ","year":"2012","unstructured":"Scott LJ. Repaglinide: a review of its use in type 2 diabetes mellitus. Drugs. 2012, 72:249-72. 10.2165\/11207600-000000000-00000","journal-title":"Drugs"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443020-00003","article-title":"Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent","volume":"43","author":"McLeod JF","year":"2004","unstructured":"McLeod JF. Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent. Clin Pharmacokinet. 2004, 43:97-120. 10.2165\/00003088-200443020-00003","journal-title":"Clin Pharmacokinet"},{"key":"ref118","article-title":"Long-term management of patients after weight loss surgery","volume":"9","author":"Richardson WS","year":"2009","unstructured":"Richardson WS, Plaisance AM, Periou L, Buquoi J, Tillery D. Long-term management of patients after weight loss surgery. Ochsner J. 2009, 9:154-9.","journal-title":"Ochsner J"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_338_18","article-title":"Questionnaire to assess adherence to diet and exercise advices for weight management in lifestyle-related diseases","volume":"8","author":"Dubasi SK","year":"2019","unstructured":"Dubasi SK, Ranjan P, Arora C, et al.. Questionnaire to assess adherence to diet and exercise advices for weight management in lifestyle-related diseases. J Family Med Prim Care. 2019, 8:689-94. 10.4103\/jfmpc.jfmpc_338_18","journal-title":"J Family Med Prim Care"},{"key":"ref120","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200111","article-title":"Bariatric surgery versus conventional medical therapy for type 2 diabetes","volume":"366","author":"Mingrone G","year":"2012","unstructured":"Mingrone G, Panunzi S, De Gaetano A, et al.. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012, 366:1577-85. 10.1056\/NEJMoa1200111","journal-title":"N Engl J Med"},{"key":"ref121","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200225","article-title":"Bariatric surgery versus intensive medical therapy in obese patients with diabetes","volume":"366","author":"Schauer PR","year":"2012","unstructured":"Schauer PR, Kashyap SR, Wolski K, et al.. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012, 366:1567-76. 10.1056\/NEJMoa1200225","journal-title":"N Engl J Med"},{"key":"ref122","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000073313.16135.21","article-title":"Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients","volume":"23","author":"Kopp HP","year":"2003","unstructured":"Kopp HP, Kopp CW, Festa A, et al.. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol. 2003, 23:1042-7. 10.1161\/01.ATV.0000073313.16135.21","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref123","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-2353","article-title":"Bariatric surgery does not exacerbate and may be beneficial for the microvascular complications of type 2 diabetes","volume":"35","author":"Miras AD","year":"2012","unstructured":"Miras AD, Chuah LL, Lascaratos G, et al.. Bariatric surgery does not exacerbate and may be beneficial for the microvascular complications of type 2 diabetes. Diabetes Care. 2012, 35:e81. 10.2337\/dc11-2353","journal-title":"Diabetes Care"},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.08.012","article-title":"Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"6","author":"Mummadi RR","year":"2008","unstructured":"Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2008, 6:1396-402. 10.1016\/j.cgh.2008.08.012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref125","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.01.042","article-title":"Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease","volume":"130","author":"Klein S","year":"2006","unstructured":"Klein S, Mittendorfer B, Eagon JC, et al.. Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology. 2006, 130:1564-72. 10.1053\/j.gastro.2006.01.042","journal-title":"Gastroenterology"},{"key":"ref126","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.10.017","article-title":"Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: a systematic review and meta-analysis","volume":"17","author":"Lee Y","year":"2019","unstructured":"Lee Y, Doumouras AG, Yu J, et al.. Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019, 17:1040-60. 10.1016\/j.cgh.2018.10.017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref127","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-015-1691-x","article-title":"Bariatric surgery and non-alcoholic fatty liver disease: a systematic review of liver biochemistry and histology","volume":"25","author":"Bower G","year":"2015","unstructured":"Bower G, Toma T, Harling L, et al.. Bariatric surgery and non-alcoholic fatty liver disease: a systematic review of liver biochemistry and histology. Obes Surg. 2015, 25:2280-9. 10.1007\/s11695-015-1691-x","journal-title":"Obes Surg"},{"key":"ref128","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-789X.2011.00866.x","article-title":"Bariatric surgery: a systematic review and network meta-analysis of randomized trials","volume":"12","author":"Padwal R","year":"2011","unstructured":"Padwal R, Klarenbach S, Wiebe N, et al.. Bariatric surgery: a systematic review and network meta-analysis of randomized trials. Obes Rev. 2011, 12:602-21. 10.1111\/j.1467-789X.2011.00866.x","journal-title":"Obes Rev"},{"key":"ref129","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.014","article-title":"Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients","volume":"149","author":"Lassailly G","year":"2015","unstructured":"Lassailly G, Caiazzo R, Buob D, et al.. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology. 2015, 149:379-88. 10.1053\/j.gastro.2015.04.014","journal-title":"Gastroenterology"},{"key":"ref130","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.12.010","article-title":"Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension","volume":"72","author":"Garcia-Tsao G","year":"2020","unstructured":"Garcia-Tsao G, Bosch J, Kayali Z, et al.. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension. J Hepatol. 2020, 72:885-95. 10.1016\/j.jhep.2019.12.010","journal-title":"J Hepatol"},{"key":"ref131","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR\u00a0trials","volume":"73","author":"Harrison SA","year":"2020","unstructured":"Harrison SA, Wong VW, Okanoue T, et al.. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR\u00a0trials. J Hepatol. 2020, 73:26-39. 10.1016\/j.jhep.2020.02.027","journal-title":"J Hepatol"},{"key":"ref132","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi ZM","year":"2019","unstructured":"Younossi ZM, Ratziu V, Loomba R, et al.. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019, 394:2184-96. 10.1016\/S0140-6736(19)33041-7","journal-title":"Lancet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/68601-non-alcoholic-fatty-liver-disease-and-its-association-with-diabetes-mellitus","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:30:27Z","timestamp":1707507027000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/68601-non-alcoholic-fatty-liver-disease-and-its-association-with-diabetes-mellitus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,20]]},"references-count":132,"URL":"https:\/\/doi.org\/10.7759\/cureus.17321","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8,20]]}}}